メリーランド州における非小細胞肺癌の臨床試験
メリーランド州内の拠点で、非小細胞肺癌に関する76件の研究が参加者を募集しています。
メリーランド州内の都市
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Luminis Health Anne Arundel Medical Center, Annapolis
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT04267848Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳以上 · 全性別 · 2026/10/02更新 · NCT02146170A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Local Institution - 0123, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07680764A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Maryland Oncology Hematology (MOH) ( Site 8102), Rockville
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Ascension Saint Agnes Hospital, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06472245A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Baltimore
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06996782Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #14, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06780085A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- UM Upper Chesapeake Hematology and Oncology - Aberdeen, Aberdeen
- UPMC Western Maryland, Cumberland
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635DK222 Study at Hopkins
- Johns Hopkins Hospital, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07140315Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Johns Hopkins University of Medicine, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Sidney Kimmel Cancer Center - Bayview Campus, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05498428Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2026/09/28更新 · NCT02682667A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Maryland Oncology Hematology, P.A., Annapolis
- Maryland Oncology Hematology, P.A., Bethesda
- Maryland Oncology Hematology, PA, Brandywine
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07144280Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/09/28更新 · NCT03412877A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Bethesda
- Research Site, Frederick
- Research Site, Silver Spring
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06868277Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Maryland Oncology Hematology, P.A., Annapolis
- Maryland Oncology Hematology, P.A., Bethesda
- Maryland Oncology Hematology, P.A., Brandywine
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Maryland, Baltimore
- Maryland Oncology Hematology P A, Silver Spring
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07154290Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- University of Maryland, Baltimore
- Johns Hopkins Bayview Medical Center, Baltimore
- James M Stockman Cancer Institute, Frederick
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Annapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06357533Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Baltimore
被験者募集中第2相
18歳〜95歳 · 全性別 · 2026/09/23更新 · NCT05061550A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0505, Annapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06561386A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0702, Annapolis
- Maryland Oncology Hematology - Columbia, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06875310A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/09/22更新 · NCT06066138Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Frederick Health Hospital- James M Stockman Cancer Institute, Frederick
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- University of Maryland Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Medstar Franklin Square, Baltimore
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT06745882A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Bethesda
- Research Site, Bethesda
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Baltimore
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06767514Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Johns Hopkins, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07349537A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- United Theranostics, Glen Burnie
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07020117Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- The Sidney Kimmel Comprehensive Cancer Center, Baltimore
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT04613596Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- John Hopkins Medical Center, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT04410796A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Johns Hopkins Bayview Medical Center, Baltimore
- USO - Maryland Oncology Hematology, Columbia
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
- Walter Reed National Military Medical Center, Bethesda
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06793215Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Baltimore
- Research Site, Brandywine
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07291037Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06343402T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/08/31更新 · NCT02133196Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Research Site, Bethesda
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/26更新 · NCT06350097ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。